Nifuratel

Nifuratel
Clinical data
AHFS/Drugs.com International Drug Names
ATC code G01AX05 (WHO)
Identifiers
CAS Number 4936-47-4 YesY
PubChem (CID) 6433427
ChemSpider 4938579
UNII U60U6P08SP YesY
KEGG D01050 YesY
ECHA InfoCard 100.023.251
Chemical and physical data
Formula C10H11N3O5S
Molar mass 285.28 g/mol
3D model (Jmol) Interactive image
  (verify)

Nifuratel (brand name Macmiror, or — in combination with nystatin, — Macmiror Complex) is a drug used in gynecology. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.

Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp.[1]

Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example, it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is Trichomonas vaginalis or Candida strains such as Candida albicans.

Side effects appear to be minimal or non-existent and it has a safe toxicological profile.[2]

References

  1. Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey
  2. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Werner Mendling, Federico Mailland Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.
This article is issued from Wikipedia - version of the 7/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.